Free tool
FAERS Monitor: Arestin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050781 or its brand name (Arestin, Minocycline Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
5,103
Serious
4,179
82% of reports
Hospitalization
2,242
Death reported
1,656
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,272
- off label use1,161
- drug intolerance966
- pain929
- rheumatoid arthritis895
- rash793
- nausea791
- arthralgia775
- drug hypersensitivity753
- joint swelling733
- fatigue699
- c-reactive protein increased680
- condition aggravated679
- headache679
- contraindicated product administered667
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 32 |
| 2005 | 38 |
| 2006 | 44 |
| 2007 | 99 |
| 2008 | 73 |
| 2009 | 57 |
| 2010 | 43 |
| 2011 | 55 |
| 2012 | 101 |
| 2013 | 45 |
| 2014 | 151 |
| 2015 | 137 |
| 2016 | 202 |
| 2017 | 230 |
| 2018 | 250 |
| 2019 | 303 |
| 2020 | 300 |
| 2021 | 256 |
| 2022 | 404 |
| 2023 | 422 |
| 2024 | 714 |
| 2025 | 802 |
| 2026 | 345 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,056 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| contraindicated product administeredSignal | 667 | 92.8 | 86.4 | 59,246 |
| c-reactive protein increasedSignal | 680 | 78.5 | 73.1 | 51,051 |
| drug intoleranceSignal | 966 | 41.6 | 39.3 | 38,050 |
| rheumatoid arthritisSignal | 895 | 32.7 | 30.8 | 27,442 |
| joint swellingSignal | 733 | 25.2 | 23.5 | 16,987 |
| drug hypersensitivitySignal | 753 | 16.1 | 15.1 | 10,703 |
| condition aggravatedSignal | 679 | 9.2 | 8.6 | 5,032 |
| arthralgiaSignal | 775 | 7.7 | 7.2 | 4,590 |
| rashSignal | 793 | 7.5 | 7.0 | 4,555 |
| painSignal | 929 | 6.2 | 5.9 | 4,200 |
| off label useSignal | 1,161 | 5.5 | 5.2 | 4,416 |
| headacheSignal | 679 | 4.5 | 4.2 | 1,878 |
| nauseaSignal | 791 | 4.1 | 3.9 | 1,939 |
| drug ineffectiveSignal | 1,272 | 4.0 | 3.8 | 3,023 |
| fatigueSignal | 699 | 3.7 | 3.5 | 1,428 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.